Pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is known to have suppressive effects on immune and inflammatory cells. We have previously shown in mice and dogs that this agent prevents primary nonfunction of islet iso-and autografts by reducing inflammation at the graft site. The present study was designed to further investigate whether pravastatin has a synergistic effect with cyclosporine (Cs) to prolong islet allograft survival in mice. Unpurified 3000 BALB/c newborn islets were transplanted under the renal capsule of a streptozotocin-diabetic C57BL/6 mouse. Pravastatin and Cs were administered for 10 days starting on the day of grafting (day 0). Five groups were set up based on the treatment protocol: group 1, treatment with 40 mg/kg pravastatin; group 2, 30 mg/kg Cs; group 3, 50 mg/ kg Cs; group 4, 40 mg/kg pravastatin and 30 mg/kg Cs; group 5, vehicle alone. Graft survival was indicated by blood glucose levels sustained at <200 mg/dl, and graft rejection by >250 mg/dl for 2 consecutive days. Hyperglycemia persisted in six of the eight (75%) mice and grafts were rejected in 3.6 ± 0.5 days (mean ± SD) in group 5. In group 1, grafts were also rejected in 3.8 ± 0.8 days, but blood glucose was transiently <200 mg/dl in three of the five mice. Despite Cs, grafts were rejected between 7 and 15 days (10.3 ± 2.4 days) in group 2. Among six mice in group 3, one maintained euglycemia for >60 days, the other rejected the graft on day 15, and the remaining four died with functioning grafts between 9 and 13 days due to Cs toxicity. A combination of a low dose of Cs and pravastatin (group 4) prolonged graft survival for >19 days in five of the eight mice, and for 7-13 days in the remaining three mice. Histological examination of the grafts in this group showed significantly reduced local inflammation. Results indicate a synergistic effect of pravastatin and Cs on prevention of islet allograft rejection.
INTRODUCTION
function by reducing inflammation around the graft (1). Pravastatin was also effective in dogs in which the number of autologous islets required for maintenance of eug-Islet transplantation has the potential to be an effective treatment for diabetes mellitus. However, success lycemia was reduced by 25% of that required in control dogs not treated with pravastatin (2). in clinical islet allotransplantation has been limited (3). Among a number of factors that lead to graft failure, we With allogeneic islets, nonspecific inflammation is followed by immune responses specific for alloantigens. have focused our previous investigations on prevention of primary islet graft nonfunction. Transplanted islets Cyclosporine (Cs) and FK506 are effective as immunosuppressants, but are also known to impair β cell func-are known to be vulnerable, especially until they are revascularized, to various insults induced by inflammation tion (7, 20) . Furthermore, steroids used in combination with these agents have detrimental effects on trans-not directly related to alloantigens. Nonspecific inflammation takes place within a short period after transplan-planted β cells (18) . Therefore, development of immunosuppressive protocols that require reduced doses of tation and causes islet damage primarily through macrophage-mediated cytokines and free radicals (13, 19) .
immunosuppressants is essential for effective clinical islet transplantation. In vitro studies with HMG-CoA re-Using islet isografts in mice, we have previously shown that treating recipients with pravastatin, an HMG-CoA ductase inhibitors have demonstrated suppression of alloimmune responses of lymphocytes (4) and of NK cell reductase inhibitor, will prevent primary islet graft non-640 ARITA ET AL.
(5) and monocyte activities (16) . In patients with a car-a 23-gauge needle, into the subcapsular space of the left kidney with 3000 unpurified BALB/c newborn islets. diac or renal allograft, pravastatin combined with the standard immunosuppressive regimen significantly re-Experimental Groups duced rejection episodes (12, 15) . These lines of evidence together with our results with islets suggested that Recipient mice were treated daily either with pravaspravastatin may be beneficial for islet transplantation by tatin, cyclosporine (Cs), or both for 10 days, starting reducing early graft loss and by acting synergistically on the day of transplantation (day 0). Pravastatin was with immunosuppressive agents. Combined treatment administered orally (PO) in 0.1 ml normal saline soluwith pravastatin may also have the potential to reduce tion, and Cs was injected intramuscularly (IM) in 0.1 ml doses of immunosuppressants required. We evaluated olive oil. Recipients were divided into the following five this possibility using islet allografts in mice.
groups based on treatment protocols: group 1 (n = 5), treated with 40 mg/kg pravastatin; group 2 (n = 8), 30 MATERIALS AND METHODS mg/kg Cs; group 3 (n = 6), 50 mg/kg Cs; group 4 (n = Animals 8), a combination of 40 mg/kg pravastatin and 30 mg/ kg Cs; group 5 (n = 8), vehicle alone (olive oil IM and BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice were obsaline PO), as controls. In addition, mice in group 1 retained from a commercial source. BALB/c breeding ceived olive oil IM, and those in groups 2 and 3 received pairs were established to obtain newborn mice that were saline PO. used as islet donors. Eight-to 12-week old male C57BL/ 6 mice were made diabetic by an IP injection of 250
Determination of Graft Survival mg/kg streptozotocin (Sigma Chemical Co., St. Louis, MO) 5 days prior to transplantation, and served as recip-Nonfasting blood glucose and urine glucose were ients. All animals were handled in compliance with the measured three times per week and used to indicate graft guidelines of the UCLA Chancellor's Animal Research survival. Blood glucose <200 mg/dl was considered to Committee and the Veterans Affairs Medical Center/ be induced by viable grafts. Blood glucose >250 mg/dl West Los Angeles Animal Research Committee for the on two consecutive tests was considered as graft failure, care and use of laboratory animals. and the period from the islet grafting to the end of normoglycemia (<200 mg/dl) was taken as graft survival Islet Preparation time. Body weight was also measured three times per The pancreas was removed from 5-to 7-day-old new-
week. When normoglycemia was maintained for 60 born mice. Pancreata were pooled and dispersed into days, a left nephrectomy was performed to examine the small fragments in cold Hanks' balanced salt solution graft histologically. For histology, the kidney carrying (HBSS, Sigma). Pancreatic fragments were digested in the graft was fixed in 10% buffered formalin, and sec-HBSS containing 1.5 mg/ml collagenase (Collagenase tions were stained with hematoxylin and eosin. P, Boehringer-Mannheim, Indianapolis, IN) by handshaking. The digests were washed twice with HBSS and Statistical Analysis cultured, without purification of islets, in plastic petri All data are expressed as mean ± SD and compared dishes (Falcon 1007, Becton Dickinson, Oxnard, CA) in using a Mann-Whitney U-test or a chi-square test. The air plus 5% CO 2 at 37°C. The medium used for culture difference between two groups was considered signifiwas RPMI-1640 supplemented with 10% fetal bovine cant if the p-value was less than 0.05. serum and 10 mM nicotinamide. After culture for 5-7 days, tissues were recovered from petri dishes and sus-RESULTS pended, without islet purification, in HBSS. Duplicate
Restoration of Normoglycemia or triplicate 50-µl aliquots were obtained from the final Following islet transplantation, blood glucose levels preparation and stained with diphenylthiocarbazone of all mice treated with Cs (groups 2-4) decreased to (Sigma) to determine total islet number. The islet num-<200 mg/dl within 3 days. In contrast, the blood glucose ber was counted without consideration of size distribufell to <200 mg/dl in only two of the eight (25%) group tion because newborn islets prepared in this manner 5 mice and in only three of the five (60%) group 1 mice. were uniform in size, ranging from 50 to 75 µm.
Little change occurred in blood glucose in the remaining Recipient Selection and Islet Transplantation mice of these two groups, and all recipients became hyperglycemic by day 4. Although a higher number of C57BL/6 recipients exhibiting >300 mg/dl blood glumice showed transient graft function in group 1 comcose (measured by ONE TOUCH, Lifescan Inc., Milpipared with group 5, the difference was not statistically tas, CA) and glycosuria (score >2 by TEW-TAPE, Elli Lilly and Co., Indianapolis, IN) were transplanted, using significant.
Islet Allograft Survival cemic mouse in group 4 on day 60 contained many wellformed islets with very few infiltrating cells and no Graft survival times in each group are summarized in thickened renal capsule. Table 1 . All islet allografts were rejected by day 4 in groups 1 and 5. Thus, pravastatin alone did not signifi-DISCUSSION cantly prolong allograft survival. Cyclosporine at a dose Isolated islets, when transplanted into a type I diaof 30 mg/kg (group 2) prolonged graft survival to 10.3 ± betic patient, are challenged by a series of different 2.4 days, but all grafts were rejected within 15 days.
types of insults that may lead to cell death. Unlike a Islet allograft survival was further improved by increassolid organ transplant, islet cells must first survive withing Cs dose of 50 mg/kg (group 3). However, four of out a direct blood supply. In the early stages of transthe six mice died of Cs toxicity while maintaining funcplantation, the supply of oxygen and nutrients must detional grafts. One of the remaining two mice rejected the pend on diffusion due to the absence of blood vessel graft on day 15, but the other maintained a viable graft connections. At the same time, islets face an attack by for >60 days. A combination of 40 mg/kg pravastatin inflammatory agents produced by infiltrating cells in reand 30 mg/kg Cs (group 4) was found to be the most sponse to dead cells contaminating the islets and to the effective. In this group, grafts survived for >19->60 tissue damage that surrounds the graft. Islets are small days in three of the eight mice, whereas the remaining cell clusters without protection, and therefore highly grafts were rejected between days 7 and 31.
vulnerable to inflammatory cells and their products. Fur-Changes in Body Weight thermore, inflammatory products such as cytokines are especially toxic to β cells. Macrophages are known to Body weight loss was calculated as: (day 0 body play a major role in inflammation-mediated primary islet weight − day 10 weight)/day 0 body weight (%). The graft destruction (13). This inflammatory process is then body weight loss after 10 days of Cs treatment in groups followed by specific immune responses directed against 2, 3, and 4 was 8.5 ± 2.3% (n = 4), 19.4 ± 5.8% (n = 4), alloantigens and by the recurrence of autoimmune reand 7.8 ± 3.2%, respectively. Mice treated with 50 mg/ sponses directed against islet-specific antigens. In order kg Cs showed severe weight loss and died of emaciato prevent immune-mediated islet destruction, immunotion, although the grafts were viable. In contrast, the suppressive agents must be administered. However, Cs, weight loss of mice treated with 30 mg Cs was moderate FK506, and steroids are additional cytotoxic insults to in both groups 2 and 4. Thus, the treatment combining islets (7, 18, 20) . Therefore, these islet toxic factors must Cs and pravastatin appeared to add no toxicity to that be reduced by every possible means to improve islet seen with Cs alone. graft performance.
Graft Histology
Research has continued to develop optimal immunosuppressive regimens for islet transplantation in type I Figure 1 is representative of the histology of the grafts in groups 2 and 4. The graft that was recovered diabetic patients. 15-Deoxyspergualin was found to be effective for prevention of primary islet graft nonfunc-from a mouse in group 2 immediately after developing hyperglycemia on day 15 showed a thickened renal cap-tion and allograft rejection in mice (14) . Rapamicin prolonged islet allograft survival in dogs when combined sule with severe fibrosis, mononuclear cell infiltration, and disintegrated islets. The graft taken from a eugly-with a low dose of Cs (22) . Mycophenolate mofetil (22) and leflunomide (9) were also effective for prolonging stimulation (unpublished data). In vivo, pravastatin prevents acute and chronic rejection of liver (11) and heart islet allograft survival in mice. The most striking results were recently presented by Shapiro et al. in type I dia-(17) allografts in rats. In patients with a heart (15) or kidney (12) transplant, pravastatin added to immunosup-betic patients in which insulin independence was achieved with an immunosuppressive regimen devoid of steroids pressive agents has been shown to reduce rejection episodes. These clinical studies may also suggest syner- (21) .
Pravastatin is widely used in patients as a cholesterol-gistic effects of pravastatin and Cs in preventing graft rejection. Our previous studies with mouse islet isografts lowering agent. This agent inhibits HMG-CoA reductase in cholesterol biosynthesis and reduces serum choles-
(1) and dog autografts (2) have clearly demonstrated the prevention of primary islet graft nonfunction by peri-terol levels with minimally adverse effects (10). In addition, HMG-CoA reductase inhibitors, including pravas-transplant treatment with pravastatin.
In the present studies, we have demonstrated the syn-tatin, have been known to have immunosuppressive effects by blocking the mevalonate pathway (6). In vitro, ergistic effect of pravastatin with low-dose Cs for prolongation of islet allograft survival in mice. We purpose-HMG-CoA reductase inhibitors inhibit lymphocyte proliferation (4), NK cell activities (5), and monocyte che-fully used unpurified newborn islets to reflect clinical islet transplantation in which islet preparations contain, motaxis (16) . Our preliminary studies in vitro also have shown that pravastatin treatment of mice decreases the in a certain extent, acinar and dead cells. The islet purity of our preparations was 20-30% and contained duct number and function of peritoneal macrophages accumulated in the peritoneal cavity following thyoglycolate cells and cell debris. These cell-contaminated islets may examination, Ms. Linda A. Shevlin for her assistance in variincrease nonspecific inflammation and also alloimmune ous areas, and Elizabeth Stein, Ph.D., for her critical review responses. Because we anticipated a higher amount of of the paper.
islet loss in allogeneic recipients, this study used 3000 islets for transplantation instead of 1800-2500 islets REFERENCES used in the previous isograft study (1). Blood glucose
